647 results on '"Harris, John E."'
Search Results
2. Baseline Levels of Circulating Inflammatory Biomarkers Stratify Patients with Vitiligo Who Significantly Repigment after Treatment with Ruxolitinib Cream
3. Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study
4. International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale.
5. CXCL9 Links Skin Inflammation and Fibrosis through CXCR3-Dependent Upregulation of Col1a1 in Fibroblasts
6. Lesional CD8+ T Cell Number Predicts Surgical Outcomes of Melanocyte-Keratinocyte Transplantation Surgery for Vitiligo
7. A Keratinocyte-Tethered Biologic Enables Location-Precise Treatment in Mouse Vitiligo
8. Regulatory T Cells Require CCR6 for Skin Migration and Local Suppression of Vitiligo
9. Multispecies-targeting siRNAs for the modulation of JAK1 in the skin
10. 501 - Efficacy and safety of upadacitinib in a phase 2 randomized, double-blind, dose-ranging study of adults with extensive non-segmental vitiligo
11. 519 - Efficacy of prolonged ruxolitinib cream treatment for vitiligo among patients with limited or no initial response at 6 months
12. RNAi-based modulation of IFN-γ signaling in skin
13. Performing Suction Blister Skin Biopsies.
14. Gene Expression Profiling in the Skin Reveals Strong Similarities between Subacute and Chronic Cutaneous Lupus that Are Distinct from Lupus Nephritis
15. Spatial characterization of interface dermatitis in cutaneous lupus reveals novel chemokine ligand-receptor pairs that drive disease
16. CXCR4 identifies transitional bone marrow premonocytes that replenish the mature monocyte pool for peripheral responses
17. Expanding the White Armor of Vitiligo
18. Vitiligo Progression in a Patient Undergoing Romosozumab Treatment for Osteoporosis
19. Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the International Vitiligo Task Force Part 1: towards a new management algorithm
20. Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international Vitiligo Task Force—Part 2: Specific treatment recommendations
21. Baseline Levels of Circulating Inflammatory Biomarkers Stratify Patients With Vitiligo Who Significantly Repigment Following Treatment With Ruxolitinib Cream
22. Mental Health and Psychosocial Quality-of-Life Burden Among Patients With Vitiligo
23. Real-world evidence on atopic dermatitis: Baseline characteristics and predictors of treatment choice in the TARGET cohort
24. Resident Memory and Recirculating Memory T Cells Cooperate to Maintain Disease in a Mouse Model of Vitiligo
25. Exploring the natural and treatment history of vitiligo: perceptions of patients and healthcare professionals from the global VALIANT study
26. Assessing risk amid uncertainty inside and outside the dermatology clinic
27. Vitiligo
28. Advancements in Targeted Therapies for Vitiligo: Prioritizing Equity in Drug Development.
29. Efficacy of prolonged ruxolitinib cream treatment for vitiligo among patients with limited or no initial response at 6 months.
30. IL-12/IL-23–Independent Function of BATF3-Dependent Dendritic Cells Is Required for Initiation of Disease in a Mouse Model of Vitiligo
31. Expanding the White Armor of Vitiligo
32. Vitiligo Induced by Dupilumab Treatment: A Case Series
33. Adolescent extra‐truncal progressive macular hypomelanosis
34. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial
35. Narrowband ultraviolet B phototherapy in pediatric vitiligo: A retrospective study
36. Keratinocyte-Derived Chemokines Orchestrate T-Cell Positioning in the Epidermis during Vitiligo and May Serve as Biomarkers of Disease
37. Fas ligand promotes an inducible TLR-dependent model of cutaneous lupus-like inflammation
38. Activation of the NLRP1 inflammasome in human keratinocytes by the dsDNA mimetic poly(dA:dT)
39. Effect of ruxolitinib cream on achievement of VASI50 by body region: Week 52 pooled analysis of the TRuE-V phase 3 studies
40. CXCL9 links skin inflammation and fibrosis via CXCR3-dependent upregulation of collagen 1a1 in fibroblasts
41. Addition of Narrow-Band UVB Phototherapy to Ruxolitinib Cream in Patients With Vitiligo
42. Pathogenesis of Vitiligo
43. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo
44. Vitiligo of the arm after COVID-19 vaccination
45. 34631 Do patients with vitiligo and health care professionals treating them recognize the burden in living with the disease in the United States? Findings from the VALIANT study
46. 34612 Exploring the natural history of vitiligo in the United States: Findings from the VALIANT study
47. Topical JAK Inhibitors for the Treatment of Alopecia Areata and Vitiligo
48. Animal models of vitiligo: Matching the model to the question
49. Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: Descriptive subgroup analyses from a phase 2, randomized, double-blind trial
50. Improvement in light tolerance with oral Polypodium leucotomos extract in a patient with nonsegmental vitiligo treated with narrow-band UV-B phototherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.